Tumor vegf

vegfr2 autocrine feed-forward loop triggers angiogenesis in lung cancer

Chatterjee Sampurna Chatterjee, Lukas C. Heukamp, Maike Siobal, Jakob Schöttle, Caroline Wieczorek, Martin Peifer, Davide Frasca, Mirjam Koker, Katharina König, Lydia Meder, Daniel Rauh, Reinhard Buettner, Jürgen Wolf, Rolf A. Brekken, Bernd Neumaier, Gerhard Christofori, Roman K. Thomas, Roland T. Ullrich

Research output: Contribution to journalArticle

105 Citations (Scopus)

Abstract

The molecular mechanisms that control the balance between antiangiogenic and proangiogenic factors and initiate the angiogenic switch in tumors remain poorly defined. By combining chemical genetics with multimodal imaging, we have identified an autocrine feed-forward loop in tumor cells in which tumor-derived VEGF stimulates VEGF production via VEGFR2-dependent activation of mTOR, substantially amplifying the initial proangiogenic signal. Disruption of this feed-forward loop by chemical perturbation or knockdown of VEGFR2 in tumor cells dramatically inhibited production of VEGF in vitro and in vivo. This disruption was sufficient to prevent tumor growth in vivo. In patients with lung cancer, we found that this VEGF:VEGFR2 feed-forward loop was active, as the level of VEGF/VEGFR2 binding in tumor cells was highly correlated to tumor angiogenesis. We further demonstrated that inhibition of tumor cell VEGFR2 induces feedback activation of the IRS/MAPK signaling cascade. Most strikingly, combined pharmacological inhibition of VEGFR2 (ZD6474) and MEK (PD0325901) in tumor cells resulted in dramatic tumor shrinkage, whereas monotherapy only modestly slowed tumor growth. Thus, a tumor cell-autonomous VEGF:VEGFR2 feed-forward loop provides signal amplification required for the establishment of fully angiogenic tumors in lung cancer. Interrupting this feed-forward loop switches tumor cells from an angiogenic to a proliferative phenotype that sensitizes tumor cells to MAPK inhibition.

Original languageEnglish (US)
Pages (from-to)1732-1740
Number of pages9
JournalJournal of Clinical Investigation
Volume123
Issue number4
DOIs
StatePublished - Apr 1 2013

Fingerprint

Vascular Endothelial Growth Factor A
Lung Neoplasms
Neoplasms
Multimodal Imaging
Angiogenesis Inducing Agents
Mitogen-Activated Protein Kinase Kinases
Growth
Pharmacology

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Sampurna Chatterjee, C., Heukamp, L. C., Siobal, M., Schöttle, J., Wieczorek, C., Peifer, M., ... Ullrich, R. T. (2013). Tumor vegf: vegfr2 autocrine feed-forward loop triggers angiogenesis in lung cancer. Journal of Clinical Investigation, 123(4), 1732-1740. https://doi.org/10.1172/JCI65385

Tumor vegf : vegfr2 autocrine feed-forward loop triggers angiogenesis in lung cancer. / Sampurna Chatterjee, Chatterjee; Heukamp, Lukas C.; Siobal, Maike; Schöttle, Jakob; Wieczorek, Caroline; Peifer, Martin; Frasca, Davide; Koker, Mirjam; König, Katharina; Meder, Lydia; Rauh, Daniel; Buettner, Reinhard; Wolf, Jürgen; Brekken, Rolf A.; Neumaier, Bernd; Christofori, Gerhard; Thomas, Roman K.; Ullrich, Roland T.

In: Journal of Clinical Investigation, Vol. 123, No. 4, 01.04.2013, p. 1732-1740.

Research output: Contribution to journalArticle

Sampurna Chatterjee, C, Heukamp, LC, Siobal, M, Schöttle, J, Wieczorek, C, Peifer, M, Frasca, D, Koker, M, König, K, Meder, L, Rauh, D, Buettner, R, Wolf, J, Brekken, RA, Neumaier, B, Christofori, G, Thomas, RK & Ullrich, RT 2013, 'Tumor vegf: vegfr2 autocrine feed-forward loop triggers angiogenesis in lung cancer', Journal of Clinical Investigation, vol. 123, no. 4, pp. 1732-1740. https://doi.org/10.1172/JCI65385
Sampurna Chatterjee C, Heukamp LC, Siobal M, Schöttle J, Wieczorek C, Peifer M et al. Tumor vegf: vegfr2 autocrine feed-forward loop triggers angiogenesis in lung cancer. Journal of Clinical Investigation. 2013 Apr 1;123(4):1732-1740. https://doi.org/10.1172/JCI65385
Sampurna Chatterjee, Chatterjee ; Heukamp, Lukas C. ; Siobal, Maike ; Schöttle, Jakob ; Wieczorek, Caroline ; Peifer, Martin ; Frasca, Davide ; Koker, Mirjam ; König, Katharina ; Meder, Lydia ; Rauh, Daniel ; Buettner, Reinhard ; Wolf, Jürgen ; Brekken, Rolf A. ; Neumaier, Bernd ; Christofori, Gerhard ; Thomas, Roman K. ; Ullrich, Roland T. / Tumor vegf : vegfr2 autocrine feed-forward loop triggers angiogenesis in lung cancer. In: Journal of Clinical Investigation. 2013 ; Vol. 123, No. 4. pp. 1732-1740.
@article{6169eb1dc1844bbda5c14f20b6b50209,
title = "Tumor vegf: vegfr2 autocrine feed-forward loop triggers angiogenesis in lung cancer",
abstract = "The molecular mechanisms that control the balance between antiangiogenic and proangiogenic factors and initiate the angiogenic switch in tumors remain poorly defined. By combining chemical genetics with multimodal imaging, we have identified an autocrine feed-forward loop in tumor cells in which tumor-derived VEGF stimulates VEGF production via VEGFR2-dependent activation of mTOR, substantially amplifying the initial proangiogenic signal. Disruption of this feed-forward loop by chemical perturbation or knockdown of VEGFR2 in tumor cells dramatically inhibited production of VEGF in vitro and in vivo. This disruption was sufficient to prevent tumor growth in vivo. In patients with lung cancer, we found that this VEGF:VEGFR2 feed-forward loop was active, as the level of VEGF/VEGFR2 binding in tumor cells was highly correlated to tumor angiogenesis. We further demonstrated that inhibition of tumor cell VEGFR2 induces feedback activation of the IRS/MAPK signaling cascade. Most strikingly, combined pharmacological inhibition of VEGFR2 (ZD6474) and MEK (PD0325901) in tumor cells resulted in dramatic tumor shrinkage, whereas monotherapy only modestly slowed tumor growth. Thus, a tumor cell-autonomous VEGF:VEGFR2 feed-forward loop provides signal amplification required for the establishment of fully angiogenic tumors in lung cancer. Interrupting this feed-forward loop switches tumor cells from an angiogenic to a proliferative phenotype that sensitizes tumor cells to MAPK inhibition.",
author = "{Sampurna Chatterjee}, Chatterjee and Heukamp, {Lukas C.} and Maike Siobal and Jakob Sch{\"o}ttle and Caroline Wieczorek and Martin Peifer and Davide Frasca and Mirjam Koker and Katharina K{\"o}nig and Lydia Meder and Daniel Rauh and Reinhard Buettner and J{\"u}rgen Wolf and Brekken, {Rolf A.} and Bernd Neumaier and Gerhard Christofori and Thomas, {Roman K.} and Ullrich, {Roland T.}",
year = "2013",
month = "4",
day = "1",
doi = "10.1172/JCI65385",
language = "English (US)",
volume = "123",
pages = "1732--1740",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "4",

}

TY - JOUR

T1 - Tumor vegf

T2 - vegfr2 autocrine feed-forward loop triggers angiogenesis in lung cancer

AU - Sampurna Chatterjee, Chatterjee

AU - Heukamp, Lukas C.

AU - Siobal, Maike

AU - Schöttle, Jakob

AU - Wieczorek, Caroline

AU - Peifer, Martin

AU - Frasca, Davide

AU - Koker, Mirjam

AU - König, Katharina

AU - Meder, Lydia

AU - Rauh, Daniel

AU - Buettner, Reinhard

AU - Wolf, Jürgen

AU - Brekken, Rolf A.

AU - Neumaier, Bernd

AU - Christofori, Gerhard

AU - Thomas, Roman K.

AU - Ullrich, Roland T.

PY - 2013/4/1

Y1 - 2013/4/1

N2 - The molecular mechanisms that control the balance between antiangiogenic and proangiogenic factors and initiate the angiogenic switch in tumors remain poorly defined. By combining chemical genetics with multimodal imaging, we have identified an autocrine feed-forward loop in tumor cells in which tumor-derived VEGF stimulates VEGF production via VEGFR2-dependent activation of mTOR, substantially amplifying the initial proangiogenic signal. Disruption of this feed-forward loop by chemical perturbation or knockdown of VEGFR2 in tumor cells dramatically inhibited production of VEGF in vitro and in vivo. This disruption was sufficient to prevent tumor growth in vivo. In patients with lung cancer, we found that this VEGF:VEGFR2 feed-forward loop was active, as the level of VEGF/VEGFR2 binding in tumor cells was highly correlated to tumor angiogenesis. We further demonstrated that inhibition of tumor cell VEGFR2 induces feedback activation of the IRS/MAPK signaling cascade. Most strikingly, combined pharmacological inhibition of VEGFR2 (ZD6474) and MEK (PD0325901) in tumor cells resulted in dramatic tumor shrinkage, whereas monotherapy only modestly slowed tumor growth. Thus, a tumor cell-autonomous VEGF:VEGFR2 feed-forward loop provides signal amplification required for the establishment of fully angiogenic tumors in lung cancer. Interrupting this feed-forward loop switches tumor cells from an angiogenic to a proliferative phenotype that sensitizes tumor cells to MAPK inhibition.

AB - The molecular mechanisms that control the balance between antiangiogenic and proangiogenic factors and initiate the angiogenic switch in tumors remain poorly defined. By combining chemical genetics with multimodal imaging, we have identified an autocrine feed-forward loop in tumor cells in which tumor-derived VEGF stimulates VEGF production via VEGFR2-dependent activation of mTOR, substantially amplifying the initial proangiogenic signal. Disruption of this feed-forward loop by chemical perturbation or knockdown of VEGFR2 in tumor cells dramatically inhibited production of VEGF in vitro and in vivo. This disruption was sufficient to prevent tumor growth in vivo. In patients with lung cancer, we found that this VEGF:VEGFR2 feed-forward loop was active, as the level of VEGF/VEGFR2 binding in tumor cells was highly correlated to tumor angiogenesis. We further demonstrated that inhibition of tumor cell VEGFR2 induces feedback activation of the IRS/MAPK signaling cascade. Most strikingly, combined pharmacological inhibition of VEGFR2 (ZD6474) and MEK (PD0325901) in tumor cells resulted in dramatic tumor shrinkage, whereas monotherapy only modestly slowed tumor growth. Thus, a tumor cell-autonomous VEGF:VEGFR2 feed-forward loop provides signal amplification required for the establishment of fully angiogenic tumors in lung cancer. Interrupting this feed-forward loop switches tumor cells from an angiogenic to a proliferative phenotype that sensitizes tumor cells to MAPK inhibition.

UR - http://www.scopus.com/inward/record.url?scp=84875846289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875846289&partnerID=8YFLogxK

U2 - 10.1172/JCI65385

DO - 10.1172/JCI65385

M3 - Article

VL - 123

SP - 1732

EP - 1740

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 4

ER -